Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Intermittent self-catheterisation in MS.
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Merck: Regulatory Update on Cladribine Tablets
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Regulation of prefrontal cortex myelination by the microbiota.
Glatiramer acetate ameliorates experimental autoimmune neuritis.
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Ustekinumab success in refractory Crohn’s disease
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Daclizumab Therapy for Multiple Sclerosis.
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.

Pages